Lars Wortmann

Lars Wortmann

Auto-generated profile, based on publicly available information

Lars Wortmann

Boehringer Ingelheim Pharma GmbH & Co., KG, Birkendorfer Str. 65, Biberach an der Riß 88397, Germany

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 January 2019 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
RHRoman C. Hillig
Roman C. Hillig
BSBrice Sautier
Brice Sautier
JSJens Schroeder
Jens Schroeder
DMDieter Moosmayer
Dieter Moosmayer
AHAndré Hilpmann
André Hilpmann
BBBenjamin Bader
Benjamin Bader
Since the late 1980s, mutations in theRASgenes have been recognized as major oncogenes with a high occurrence rate in human cancers. Such mutations reduce the ability of the small GTPase RAS to hydrolyze GTP, keeping this molecular switch in a constitutively active GTP-bound form that drives, unchecked, oncogenic downstream signaling. One strategy to reduce the levels of active RAS is to target guanine nucleotide exchange factors, which allow RAS to cycle from the inactive GDP-bound state to the active GTP-bound form. Here, we describe the identification of potent and cell-active small-molecule inhibitors which efficiently disrupt the interaction between KRAS and its exchange factor SOS1, a mode of action confirmed by a series of biophysical techniques. The binding sites, mode of action, and selectivity were elucidated using crystal structures of KRASG12C–SOS1, SOS1, and SOS2. By preventing formation of the KRAS–SOS1 complex, these inhibitors block reloading of KRAS with GTP, leading to antiproliferative activity. The final compound 23 (BAY-293) selectively inhibits the KRAS–SOS1 interaction with an IC50of 21 nM and is a valuable chemical probe for future investigations.

1 January 2020 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
PDF file
AWAntje M. Wengner
Antje M. Wengner
GSGerhard Siemeister
Gerhard Siemeister
ULUlrich Lücking
Ulrich Lücking
JLJulien Lefranc
Julien Lefranc
LWLars Wortmann
Lars Wortmann
DMDominik Mumberg
Dominik Mumberg
The DNA damage response (DDR) secures the integrity of the genome of eukaryotic cells. DDR deficiencies can promote tumorigenesis but concurrently may increase dependence on alternative repair pathways. The ataxia telangiectasia and Rad3-related (ATR) kinase plays a central role in the DDR by activating essential signaling pathways of DNA damage repair. Here, we studied the effect of the novel selective ATR kinase inhibitor BAY 1895344 on tumor cell growth and viability. Potent antiproliferative activity was demonstrated in a broad spectrum of human tumor cell lines. BAY 1895344 exhibited strong monotherapy efficacy in cancer xenograft models that carry DNA damage repair deficiencies. The combination of BAY 1895344 with DNA damage–inducing chemotherapy or external beam radiotherapy (EBRT) showed synergistic antitumor activity. Combination treatment with BAY 1895344 and DDR inhibitors achieved strong synergistic antiproliferative activity in vitro, and combined inhibition of ATR and PARP signaling using olaparib demonstrated synergistic antitumor activity in vivo. Furthermore, the combination of BAY 1895344 with the novel, nonsteroidal androgen receptor antagonist darolutamide resulted in significantly improved antitumor efficacy compared with respective single-agent treatments in hormone-dependent prostate cancer, and addition of EBRT resulted in even further enhanced antitumor efficacy. Thus, the ATR inhibitor BAY 1895344 may provide new therapeutic options for the treatment of cancers with certain DDR deficiencies in monotherapy and in combination with DNA damage–inducing or DNA repair–compromising cancer therapies by improving their efficacy.

19 May 2020 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
PDF file
LLLaura M. Luh
Laura M. Luh
USUlrike Scheib
Ulrike Scheib
KJKatrin Juenemann
Katrin Juenemann
LWLars Wortmann
Lars Wortmann
MBMichael Brands
Michael Brands
PCPhilipp M. Cromm
Philipp M. Cromm
Targeted protein degradation (TPD), the ability to control a proteins fate by triggering its degradation in a highly selective and effective manner, has created tremendous excitement in chemical biology and drug discovery within the past decades. The TPD field is spearheaded by small molecule induced protein degradation with molecular glues and proteolysis targeting chimeras (PROTACs) paving the way to expand the druggable space and to create a new paradigm in drug discovery. However, besides the therapeutic angle of TPD a plethora of novel techniques to modulate and control protein levels have been developed. This enables chemical biologists to better understand protein function and to discover and verify new therapeutic targets. This Review gives a comprehensive overview of chemical biology techniques inducing TPD. It explains the strengths and weaknesses of these methods in the context of drug discovery and discusses their future potential from a medicinal chemist's perspective.

1 October 2007 in Molecular Biology of the Cell
Verified
Journal Article
Closed access
ASAnna Santamaria
Anna Santamaria
RNRüdiger Neef
Rüdiger Neef
UEUwe Eberspächer
Uwe Eberspächer
KEKnut Eis
Knut Eis
MHManfred Husemann
Manfred Husemann
ENErich A. Nigg
Erich A. Nigg
Polo-like kinase 1 (Plk1) is a key regulator of mitotic progression and cell division in eukaryotes. It is highly expressed in tumor cells and considered a potential target for cancer therapy. Here, we report the discovery and application of a novel potent small-molecule inhibitor of mammalian Plk1, ZK-Thiazolidinone (TAL). We have extensively characterized TAL in vitro and addressed TAL specificity within cells by studying Plk1 functions in sister chromatid separation, centrosome maturation, and spindle assembly. Moreover, we have used TAL for a detailed analysis of Plk1 in relation to PICH and PRC1, two prominent interaction partners implicated in spindle assembly checkpoint function and cytokinesis, respectively. Specifically, we show that Plk1, when inactivated by TAL, spreads over the arms of chromosomes, resembling the localization of its binding partner PICH, and that both proteins are mutually dependent on each other for correct localization. Finally, we show that Plk1 activity is essential for cleavage furrow formation and ingression, leading to successful cytokinesis.

4 February 2000 in Accounts of Chemical Research
Verified
Journal Article
Closed access
DEDieter Enders
Dieter Enders
LWLars Wortmann
Lars Wortmann
RPRené Peters
René Peters

5 June 2020 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
ULUlrich Lücking
Ulrich Lücking
LWLars Wortmann
Lars Wortmann
AWAntje M. Wengner
Antje M. Wengner
JLJulien Lefranc
Julien Lefranc
PLPhilip Lienau
Philip Lienau
FNFranz von Nussbaum
Franz von Nussbaum